Eris Lifesciences delivered robust financial performance in Q1 FY27, with consolidated net profit surging 14.5% year-on-year to ₹143 crore, compared with ₹125 crore in the corresponding quarter of the previous fiscal year. According to latest reports, the pharmaceutical company's stock responded positively to the results, with shares rising 2.64% to close at ₹1,428.20 on the BSE on Wednesday. The profit growth outpaced revenue growth despite some margin pressure, demonstrating the company's operational efficiency and market positioning strength.
The company's revenue from operations demonstrated solid growth momentum, increasing 13% YoY to ₹873 crore during the quarter. As reported by Moneycontrol, revenue growth was driven by strong performance across key therapy segments, with the domestic branded formulations (DBF) business recording 14.2% growth to ₹801 crore. Among therapy segments, insulin grew 27.7%, oncology and nephrology expanded 31.3%, and vitamins, minerals and nutrients rose 19.9%, outperforming the broader market. However, growth in oral anti-diabetes and cardiac therapies, which together account for around 35% of Eris's portfolio, lagged the market, with management identifying improving performance in these segments as a key priority over the next two quarters.
Despite revenue growth, EBITDA margin contracted during the quarter, falling to 33.9% in Q1 FY27 from 35.8% in Q1 FY26. According to Moneycontrol, this margin compression was attributed to a higher contribution from biologics, including insulin and GLP-1 products. The company's total expenses rose 13% on year to ₹695.75 crore from ₹615.48 crore, contributing to the margin pressure. However, the company generated operating cash flow equivalent to 77% of EBITDA and incurred capital expenditure of ₹88 crore during the quarter. The effective tax rate also declined to 20% from 22.5% a year earlier, supporting bottom-line growth.
The insulin business remained a key growth driver, with Eris's share in the represented insulin market, comprising regular human insulin (RHI) and glargine, increasing to 16% from 9% since the Biocon acquisition, enabling the company to deliver 26.4% growth in a market that is otherwise contracting. Chairman and Managing Director Amit Bakshi highlighted that the insulin franchise continued to gain market share across products. The company's GLP-1 brand Sundae made a strong debut, emerging as the top-ranked product by prescriptions and sales volume during the quarter, with Sundae capturing around 21% prescription share and nearly 20% unit share by June 2026. The generic semaglutide market recorded sales of about ₹88 crore during the quarter, with Sundae contributing ₹12 crore.
Eris Lifesciences has been on an active dealmaking run over the past year as it deepens its play in injectables and speciality formulations. In November 2025, the company's board approved buying out the remaining 30% stake in its subsidiary Swiss Parenterals for a total cash consideration of ₹423.3 crore, structured entirely as a share swap rather than a cash payout. In February 2026, Eris entered a partnership with Natco Pharma to jointly commercialise Semaglutide in India, building on its existing GLP-1 push through its own semaglutide brand, Sundae. Separately, in March 2026, Eris's board approved a ₹50 crore acquisition of the branded probiotics business from Velbiom Probiotics, giving the company entry into the microbiome-therapy segment with formulations targeting metabolic health, gut wellness and women's health.
Looking ahead, the company plans to commercialise its biologics venture, Eris Bionxt, enter the insulin analogues market from FY28, sustain momentum in its GLP-1 franchise and complete compliance-related work at Swiss Parenterals. The Swiss Parenterals business reported 5% revenue growth to ₹72 crore, although EBITDA declined 19% to ₹18 crore, with corrective and preventive actions related to European Union compliance underway and facilities expected to be audit-ready by December 2026. The company's diversified revenue streams across domestic and international markets, combined with strong performance in high-growth therapy segments like insulin and GLP-1, position it well for continued growth in the competitive pharmaceutical landscape.
